Showing results (141-150 of 174) with videos related to
Sort By:
Pageof 18
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II TrialSilvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerMatthew P Goetz, Masakazu Toi, Mario Campone, et al.Journal of the National Cancer Institute|May 15, 2020
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Fabiola Giudici, Mario Giuliano, et al.Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 9, 2012
The nutritional risk in oncology: a study of 1,453 cancer outpatientsFederico Bozzetti, Luigi Mariani, Salvatore Lo Vullo, et al.Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.Cancers|April 3, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Mario Giuliano, Fabiola Giudici, et al.The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.Pageof 18